Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder

Current Urology Reports

Volumn 5, Issue 6, 2004, Pages 423-426

  Staskin, David R ^a   Harnett, Mark D ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

Daytime Sleepiness; Overactive Bladder; Oxybutynin; Tolterodine; Trospium

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NORTROPANE DERIVATIVE; TROSPIUM CHLORIDE;

ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SLEEP STAGE; SOMNOLENCE; URINE INCONTINENCE;

DISORDERS OF EXCESSIVE SOMNOLENCE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NORTROPANES; PARASYMPATHOLYTICS; SLEEP STAGES; URINARY INCONTINENCE;

EID: 16644383514     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-004-0064-0     Document Type: Article

References (9)

1. Ditropan XL product package insert. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; June 30, 2004.
2. Kerrebroeck PV, Kreder K, Jonas U: Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001, 57:414–421. DOI: 10.1016/S0090-4295(00)01113-4
3. Rudy D, Kline K, Goldberg K: A multicenter, randomized, placebocontrolled trial of trospium chloride in overactive bladder patients [Abstract 144]. Neurourol Urodyn 2004, 23:600–601. Reports on efficacy and safety findings of large, double-blind, placebo-controlled phase-3 study of trospium chloride in patients with overactive bladder.
4. Date on file. Indevus Pharmaceuticals, Inc., Lexington, MA.
5. Pietzko A, Dimpfel W, Schwantes U, et al.: Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994, 47:337–343. DOI: 10.1007/BF00191165
6. Dimpfel W, Todorova A, Vonderheid B: Electrophysiological evaluation of potential adverse effects of tolterodine, oxybutynin, and trospium chloride on the central nervous system [Abstract]. Neurourol Urodyn 2000, 19:497–498.
7. Herberg KW: General and traffic safety and the effects of incontinence medication: new studies on the safety potential of urological anticholinergics. Die Medizinishce Welt 1999, 50:217–222.
8. Breuel HP, Murtz G, Bondy S, et al.: Safety and tolerance of trospium chloride in the high dose range. Arzneimittelforschung 1993, 43:461–464.
9. Hoddes E, Zarcone V, Smythe H, et al.: Quantification of sleepiness: a new approach. Psychophysiology 1973, 10:431–436. Provides summary of the validation of the Stanford Sleepiness Scale. DOI: 10.1111/j.1469-8986.1973.tb00801.x